What is mycophenolate mofetil (CellCept®)?

Mycophenolate mofetil is a relatively new immunosuppressive drug approved for use in certain organ transplant patients to prevent organ rejection. It has not yet been proven to be effective for myasthenia gravis (MG). Studies to determine the safety and effectiveness of mycophenolate mofetil in MG are necessary. Researchers are actively studying this promising new therapy in certain patients with MG by conducting clinical trials. Clinical trials are the safest and quickest way to find new treatments that work.

This publication is intended to provide the reader with general information to be used solely for educational purposes. As such, it does not address individual patient needs, and should not be used as a basis for decision making concerning diagnosis, care, or treatment of any condition. Instead, such decisions should be based upon the advice of a physician or health care professional who is directly familiar with the patient. The information contained in this publication reflects the views of the authors, but not necessarily those of the Myasthenia Gravis Foundation of America (MGFA). Any reference to a particular product, source, or use does not constitute an endorsement.

MGFA, its agents, employees, directors, volunteers, its Medical/Scientific Advisory Board, and its Nurses Advisory Board or their members make no warranty concerning the information contained in this publication. They specifically disclaim any warranty of merchantability, fitness for any particular purpose, or reliability regarding the information contained herein, and assume no responsibility for any damage or liability resulting from the use of such information.

© 2010 by Myasthenia Gravis Foundation of America, Inc.

Approved by the MGFA Medical/Scientific and Nurses Advisory Boards
How does mycophenolate mofetil work?
People with MG may benefit from therapy with mycophenolate mofetil when other immunosuppressive treatments have been ineffective or contraindicated. Mycophenolate mofetil suppresses the immune system and reduces the production of antibodies attacking the receptor sites of the neuromuscular junction.

What are some special considerations to discuss with your health care provider before starting mycophenolate mofetil?
Before prescribing mycophenolate mofetil, your MG physician will ask you if you have anemia or any blood conditions, unusual bleeding or bruising, or any viral or bacterial infections. If you are a woman, your physician will want to know if you are pregnant, planning on getting pregnant, or breast feeding.

In laboratory studies, mycophenolate mofetil has been reported to cause birth defects in animals. Although the effects are not known in humans, women of childbearing age should avoid becoming pregnant while taking the drug. Women who are planning a pregnancy or who become pregnant while taking mycophenolate mofetil should discuss potential risks and options with their physician.

How should mycophenolate mofetil be taken?
Mycophenolate mofetil is an oral medication that should be taken exactly as prescribed by your MG physician. Swallow the tablet or capsule with water. Do not crush the tablet or open the capsule. If your skin comes in contact with the contents of the capsule or a broken tablet, rinse thoroughly with water. Be certain to take this medication exactly as prescribed at regular intervals. If you miss a dose of mycophenolate mofetil, take it as soon as you can. If it is almost time for the next dose, take only that dose. Never take extra medicine or double doses.

Does mycophenolate mofetil interact with other medicines?
Mycophenolate mofetil can interact with other drugs. For this reason, it is important to tell your physician about all other medicines that you are taking. Be certain to mention all over-the-counter drugs, nutritional supplements or any herbal products that you are using. Antacids, vaccines, cholestyramine (a cholesterol reducing drug) and drugs that suppress your immune system can interact with mycophenolate mofetil.

What are the possible adverse effects of mycophenolate mofetil?
Your physician will carefully monitor your situation for potential adverse effects. People with MG take much smaller doses of mycophenolate mofetil than those using it to avoid transplant rejection. For this reason, common adverse effects are limited and mainly related to gastrointestinal problems including nausea and diarrhea, low white blood counts, anemia and skin rash. Mycophenolate mofetil slightly reduces resistance to infection. It is important to avoid individuals with infectious illnesses and to notify your physician if you develop persistent signs of infection.

How will a physician monitor a patient taking mycophenolate mofetil?
Appointments will be scheduled at regular intervals to monitor patient progress. At these appointments, your physician will ask you a series of questions as well as perform physical examinations and laboratory tests that provide important information to evaluate the safety and effectiveness of mycophenolate mofetil in MG. To watch for anemia or a decrease in the white cell count, blood samples will be examined frequently during the first few months of this therapy and then less often.